financetom
Business
financetom
/
Business
/
Genuine Parts' 2025 Outlook Under Scrutiny as Weak Demand Environment Persists, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Genuine Parts' 2025 Outlook Under Scrutiny as Weak Demand Environment Persists, UBS Says
Feb 19, 2025 1:06 PM

03:30 PM EST, 02/19/2025 (MT Newswires) -- Genuine Parts ( GPC ) is facing questions about its 2025 outlook as the business environment remains challenging, following its mixed Q4 results, UBS said Wednesday in a note.

"The key question remains whether there's enough support to conclude that its initial guidance for 2025 is achievable," UBS said as Genuine Parts ( GPC ) on Tuesday issued adjusted diluted earnings per share guidance of $7.75 to $8.25 on sales growth of 2% to 4%.

UBS revised its earnings per share estimates to $7.80 from $8.20 for 2025, and to $8.75 from $9 for 2026, as it sees weak demand still pressuring sales in the near term.

On a positive note, the firm said Genuine Parts ( GPC ) has options to shape its future, including pursuing acquisitions, and expects to continue its cost reduction program.

UBS reiterated its neutral rating on the stock and $125 price target.

Price: 122.00, Change: +0.35, Percent Change: +0.29

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Street Color: AstraZeneca Said In Talks With Summit to License Lung Cancer Drug in $15 Billion Deal, Bloomberg Reports
--Street Color: AstraZeneca Said In Talks With Summit to License Lung Cancer Drug in $15 Billion Deal, Bloomberg Reports
Jul 3, 2025
10:27 AM EDT, 07/03/2025 (MT Newswires) -- Price: 69.48, Change: -1.65, Percent Change: -2.32 ...
Market Chatter: Astrazeneca Said in Talks With Summit on $15 Billion Partnership
Market Chatter: Astrazeneca Said in Talks With Summit on $15 Billion Partnership
Jul 3, 2025
10:24 AM EDT, 07/03/2025 (MT Newswires) -- AstraZeneca ( AZN ) is in talks with Summit Therapeutics ( SMMT ) on a partnership deal in which it could pay as much as $15 billion over time to license a drug to treat lung cancer, Bloomberg reported, citing people familiar with the matter. AstraZeneca ( AZN ) and Summit did not...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Nvidia set to become the world's most valuable company in history
Nvidia set to become the world's most valuable company in history
Jul 3, 2025
(Reuters) -Nvidia ( NVDA ) was on track to become the most valuable company in history on Thursday, with the chipmaker's market capitalization reaching $3.92 trillion as Wall Street doubled down on optimism about AI. Shares of the leading designer of high-end AI chips were up 2.2% at $160.6 in morning trading, giving the company a higher market capitalization than...
Copyright 2023-2026 - www.financetom.com All Rights Reserved